ArticleJournal of clinical medicine2022
Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis - Results from a three-armed RCT.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis.Life (Basel, Switzerland) · 2026Article
- Sequential Keratolytic Pre-Treatment Followed by Tirbanibulin in Hyperkeratotic Actinic Keratoses: A Retrospective Comparative Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficacy of 4% 5-Fluorouracil Cream in the Treatment of Actinic Keratoses: A Single-Center Experience.Journal of clinical medicine · 2026Article
- Tirbanibulin 1% Ointment for the Treatment of Hyperkeratotic Actinic Keratosis.The Journal of dermatology · 2025Article
- Field Cancerization Treatment with Tirbanibulin 1% Ointment: Results in Real-World Practice.Acta dermato-venereologica · 2025Article
- Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Image-enhanced endoscopy in upper gastrointestinal disease: focusing on texture and color enhancement imaging and red dichromatic imaging.Clinical endoscopy · 2025Review
- Association Between Local Skin Reactions and Efficacy with 5-Fluorouracil 4% Cream in Actinic Keratosis: A Post-Hoc Analysis of Two Randomised Clinical Trials.Dermatology and therapy · 2025Article
- Exploring Anti-Aging Effects of Topical Treatments for Actinic Keratosis.Medicina (Kaunas, Lithuania) · 2025Review
- The Skin-Lightening Power of Tirbanibulin 1% Ointment.Dermatology and therapy · 2025Article
- [Update in the diagnosis and treatment of actinic keratosis].Dermatologie (Heidelberg, Germany) · 2024Review
- Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.Dermatology practical & conceptual · 2024Review
- Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience.Dermatology and therapy · 2024Article
- Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study.Medicina (Kaunas, Lithuania) · 2024Article
- Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion.Acta dermato-venereologica · 2023Review
- Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study.Journal of clinical medicine · 2023Article
- Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland.PharmacoEconomics - open · 2023Article
- Update on the Molecular Pathology of Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
- Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment.Oncology research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actinic keratosis (AK) is a chronic skin condition that may progress to cutaneous squamous cell carcinoma. We conducted a systematic review of efficacy and safety for key treatments for AK of the face and scalp, including the novel 5-day tirbanibulin 1% ointment. MEDLINE, PubMed, Embase, Cochrane Library, clinical trial registries and regulatory body websites were searched. The review included 46 studies, of which 35 studies included interventions commonly used in Europe and were sufficiently homogenous to inform a Bayesian network meta-analysis of complete clearance against topical placebo or vehicle. The network meta-analysis revealed the following odds ratios and 95% credible intervals: cryosurgery 13.4 (6.2-30.3); diclofenac 3% 2.9 (1.9-4.3); fluorouracil 0.5% + salicylic acid 7.6 (4.6-13.5); fluorouracil 4% 30.3 (9.1-144.7); fluorouracil 5% 35.0 (10.2-164.4); imiquimod 3.75% 8.5 (3.5-22.4); imiquimod 5% 17.9 (9.1-36.6); ingenol mebutate 0.015% 12.5 (8.1-19.9); photodynamic therapy with aminolevulinic acid 24.1 (10.9-52.8); photodynamic therapy with methyl aminolevulinate 11.7 (6.0-21.9); tirbanibulin 1% 11.1 (6.2-20.9). Four sensitivity analyses, from studies assessing efficacy after one treatment cycle only, for ≤25 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.